OcuTerra Appoints Barbara Ryan to Board of Directors
Retrieved on:
Tuesday, December 14, 2021
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Therapy, Wall Street, The Advisory Board Company, Board of directors, Severe cognitive impairment, Board, Medication, Bausch Health, Retina, Industry, Deutsch, Pleasure, Mink, SEC, Perrigo, Safety, Patient, Disease, Diabetic retinopathy, Eye, Allergan, Mylan, VEGF, Behind the Red Door (film), Â, View, Pharmaceutical industry, Baxalta
OcuTerra Therapeutics, Inc. (OcuTerra), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of watch and wait does not prevent or control the progression of disease, today announced the appointment of Barbara Ryan to its Board of Directors.
Key Points:
- OcuTerra Therapeutics, Inc. (OcuTerra), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of watch and wait does not prevent or control the progression of disease, today announced the appointment of Barbara Ryan to its Board of Directors.
- On behalf of OcuTerra, I want to thank Bob for all of his hard work, contributions and dedication to OcuTerra over the past few years.
- It is my pleasure to welcome Barbara to OcuTerras Board and work with her as we execute our vision to develop an earlier intervention in diabetic retinopathy, said Brent Saunders, Chairman of the Board of OcuTerra.
- In addition, for more than 14 years, Ms. Ryan has served as a columnist and editorial advisory board member to Pharmaceutical Executive Magazine.